A startup using AI to find new treatments for rare diseases just raised $121 million. Here’s why its CEO still has a dire prediction for the industry.

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 25 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 51%

Nigeria News News

Nigeria Nigeria Latest News,Nigeria Nigeria Headlines

'We are just coming off a peak hype cycle and about to go through the valley of disillusionment,' he says.

But ultimately,"I think it's hard to build a super-valuable business that changes the industry if you're focused on a single swathe. And that's where 90-plus-percent of the companies are," Gibson said in an interview at Business Insider's New York City headquarters in June.

Recursion has raised $333.7 million total, including the Series C, with a $646 million valuation, according to PitchBook.Creating a new drug takes a decade and costs a fortune. Investors have poured almost $1 billion into startups trying to change that. "Candidly, I think big pharma is asleep behind the wheel" in this area, Dar said. Lux Capital has $1.5 billion under management, and Recursion is"one of our biggest positions across our funds," Dar said.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 729. in NG

Nigeria Nigeria Latest News, Nigeria Nigeria Headlines